A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma

Trial Profile

A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Zibotentan (Primary)
  • Indications Kidney disorders; Renal failure; Renal impairment; Scleroderma
  • Focus Biomarker; Therapeutic Use
  • Acronyms ZEBRA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2015 Accrual to date is 19% according to United Kingdom Clinical Research Network.
    • 07 Aug 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top